An Immunohistochemistry Proved Extensive Inflammatory Myofibroblastic Tumour of Lung: Being Treated with Crizotinib
Satadru Biswas *
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Bidisha Bandyopadhyay
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Hambir Chowdhury
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Kuntal Ray
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Debanti Banerjee
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Ritam Joarder
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Souvik Paul
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Debapriya Mondal
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Sukanta Chakraborty
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
Chhaya Roy
Department of Radiation Oncology, R.G. Kar Medical College and Hospital, Kolkata, India
*Author to whom correspondence should be addressed.
Abstract
Inflammatory Myofibroblastic Tumour (IMT) is a rare entity which constitutes 0.04–1.2% of all lung tumours. Though IMT was first described as an ‘Interesting Benign Lung Tumour’, recurrence, the discovery of cytogenetic aberrations, a clonal population of cells and oncogenic protein overexpression establish it as a malignant entity. Because of similar morphology of a number of tumours comprising of spindle cells with inflammatory background only immunohistochemical investigations can conclude the correct final diagnoses. Interestingly, half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus. Though complete resection is the treatment of choice, ALK positivity opens the door for Crizotinib for the treatment of invasive, unresectable, recurrent IMTs.
We report a case of an aggressive, large IMT of Left Lung with contralateral multiple nodular lung metastasis in a 50 years old male patient. From ALK locus rearrangement, this case is being treated with Crizotinib and patient has improved symptomatically after 8 weeks of treatment.
Keywords: IMT, myofibroblastic, rare ca lung, crizotinib